The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.
Bibliographical noteFunding Information:
This work was supported by the Wellcome Trust (grant numbers WT101766 to G. P. and WT102807 to M. M.). All authors were supported by the University College London Hospitals Comprehensive Biomedical Research Centre Infection Theme.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
- IV antibiotics